Author details

Full Name

Anthony G Wilson

Affiliation

ORCID

Career Start Year

1992

Papers

160

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37389432	A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures.		2023
37699653	HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis.		2023
36810200	Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.		2023
35377444	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy.	Rheumatology (Oxford)	2022
36081777	Tibiofemoral knee osteoarthritis progresses symmetrically by knee compartment in the GOGO cohort.	Osteoarthr Cartil Open	2022
32969189	A Novel RELA Truncating Mutation in a Familial BehÃ§et's Disease-like Mucocutaneous Ulcerative Condition.	Arthritis and Rheumatology	2021
33964978	Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.		2021
33691749	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.		2021
33124499	Pharmacogenetics of TNF inhibitorÂ response in rheumatoid arthritis utilizing the two-component disease activity score.	Pharmacogenomics	2020
31598719	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis.	Rheumatology	2020
31852669	Interleukin 1 receptor antagonist (<i>IL1RN</i>) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease.	Ann Rheum Dis	2020
32475078	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs.	Arthritis Rheumatol	2020
31652652	Association of the Rheumatoid Arthritis Severity Variant rs26232 with the Invasive Activity of Synovial Fibroblasts.	Cells	2019
31602041	Can machine learning predict responses to TNF inhibitors?	Nature reviews. Rheumatology	2019
30166627	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis.	Pharmacogenomics J	2018
28096457	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort.	Rheumatology	2017
28836487	DNA methylation as a marker of response in rheumatoid arthritis.	Pharmacogenomics	2017
28707487	The role of genetic analysis for predicting outcome of rheumatoid arthritis.	Expert Review of Molecular Diagnostics	2017
29177082	Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases.	RMD Open	2017
29287118	Serum N-propeptide of collagen IIA (PIIANP) as a marker of radiographic osteoarthritis burden.	PLoS ONE	2017
27245864	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.	Annals of the Rheumatic Diseases	2017
27565176	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.	Rheumatology	2016
27180831	Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort.	Pharmacogenomics	2016
26814849	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis.	Arthritis and Rheumatology	2016
25213131	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.	Rheumatology	2015
25885039	Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.		2015
25919528	Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response.	JAMA	2015
26316022	C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis.	Proceedings of the National Academy of Sciences of the United States of America	2015
26312870	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis.	Lancet, The	2015
26337638	Genome-wide association meta-analyses to identify common genetic variants associated with hallux valgus in Caucasian and African Americans.	J Med Genet	2015
26109489	Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.	Arthritis and Rheumatology	2015
26152200	Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis.	Human Molecular Genetics	2015
26667261	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.		2015
24886600	A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis.	Arthritis Res Ther	2014
24449572	Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association study.	Arthritis and Rheumatology	2014
23856853	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Stu	Pharmacogenomics Journal	2014
24339425	Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis.	Arthritis Care and Research	2014
24026248	The emerging role of epigenetics in rheumatic diseases.	Rheumatology	2014
24323394	Testing the role of vitamin D in response to antitumour necrosis factor Î± therapy in a UK cohort: a Mendelian randomisation approach.	Annals of the Rheumatic Diseases	2014
23687262	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.	Annals of the Rheumatic Diseases	2014
24535543	Genetic and epigenetic predictors of responsiveness to treatment in RA.	Nature reviews. Rheumatology	2014
23697938	The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes.	Biochemical Society Transactions	2013
23817893	Allele-dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis.	Arthritis Rheum	2013
23983153	Association of genetic variants in the IL4 and IL4R genes with the severity of joint damage in rheumatoid arthritis: a study in seven cohorts.	Arthritis Rheum	2013
24068971	Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking.	PLoS Genetics	2013
24022229	Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data.		2013
23440692	A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis.	Arthritis Rheum	2013
23637320	Metaanalysis of the association of smoking and PTPN22 R620W genotype on autoantibody status and radiological erosions in rheumatoid arthritis.	Journal of Rheumatology	2013
23555300	Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.	PLoS Genet	2013
23041840	Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis.	Ann Rheum Dis	2013